researchdrivelogo.jpg
Global Respiratory Disease Testing Market Expected to Garner a Revenue of $20.1 Billion by 2027, despite COVID-19 Crisis | | Declared by Research Dive
September 14, 2022 09:02 ET | Research Dive
New York, USA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global respiratory disease testing market is anticipated to generate a revenue of $20.1...
QT Imaging Sees New Milestone Success with Blinded Medical Trials of Its Market-Disruptive Breakthrough Body Scanning Technology
August 04, 2022 10:01 ET | US Capital Global
San Francisco, California, USA, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Last year, US Capital Global Securities LLC launched a convertible note offering of up to $30 million for QT Imaging, Inc. (“QT...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast
July 21, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular...
QT Imaging, Inc. Announces Plans to Go Public through a De-SPAC Merger
June 06, 2022 17:46 ET | US Capital Global
San Francisco, California, USA, June 06, 2022 (GLOBE NEWSWIRE) -- Following continued international expansion in Q1 2022, QT Imaging, Inc. (“QT Imaging”) today announced its intention to become a...
TIP_link_300x300.jpg
Respiratory Care Devices Market Revenue to Cross $32.7Bn by 2028 at 8.9% CAGR – Exclusive Report by The Insight Partners
June 01, 2022 07:30 ET | The Insight Partners
New York, June 01, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on Respiratory Care Devices Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by...
Logo 1.png
Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults
April 19, 2022 08:05 ET | Aeterna Zentaris Inc
– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin® / Macrilen™ in Europe as the Company plans to pursue even greater protection TORONTO, ONTARIO,...
Tribun Health Ranks 'Best in Klas' - Top Performing Vendor in Digital Pathology for 2022
February 23, 2022 07:00 ET | Tribun Health
Paris, France, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Tribun Health (Formerly Tribvn Healthcare) today announced it has won the prestigious customer satisfaction award "Best in KLAS" for Digital...
MicroGenDX First Independent Commercial Lab in US Offering NGS for Infections to Appeal Directly to Patients
January 24, 2022 18:07 ET | Microgen Diagnostics
ORLANDO, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Using national TV, radio, and web media campaigns, Microgen Diagnostics will be the first independent commercial lab in the U.S. to appeal directly...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering
January 03, 2022 17:07 ET | Interpace Biosciences, Inc.
Proceeds to be used to fund the organic growth and prospective product line acquisitions PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”)...
Rome Foundation Releases Clinical Criteria to Better Meet Needs of Patients
November 29, 2021 09:00 ET | Rome Foundation
RALEIGH, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- The Rome Foundation has published a groundbreaking modification of the Rome IV diagnostic criteria of the Disorders of Gut Brain Interaction (DGBI -...